CERS

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

Retrieved on: 
Tuesday, February 20, 2024

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through March 19, 2024.

Cerus Corporation to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 1, 2024

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
  • Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
  • A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s website after the event.

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update

Retrieved on: 
Monday, January 8, 2024

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024.
  • Cerus’ unaudited preliminary product revenue for the fourth quarter of 2023 totaled $46.8 million, representing an increase of 6% over the $44.0 million recognized during the fourth quarter of 2022 and 18% sequentially.
  • The Company expects its unaudited preliminary full-year 2023 product revenue to be $156.4 million, in line with the Company’s 2023 product revenue guidance range of $155-$158 million.
  • “Additionally, we continue to expect to realize adjusted EBITDA breakeven for the fourth quarter 2023 when we report complete fourth quarter 2023 and year-end results,” continued Greenman.

Cerus Corporation to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, November 3, 2023

Cerus Corporation (NASDAQ:CERS) announced today that the Company will participate in two upcoming investor conferences:

Key Points: 
  • Cerus Corporation (NASDAQ:CERS) announced today that the Company will participate in two upcoming investor conferences:
    William “Obi” Greenman, Cerus’ president and chief executive officer, is scheduled to participate in a fireside chat at The Stifel 2023 Healthcare Conference on Tuesday, November 14th, at 4:10 p.m. EST, at the Lotte New York Palace Hotel.
  • A live webcast of the fireside chat will be available here .
  • Kevin Green, Cerus’ vice president and chief financial officer, is scheduled to participate in a fireside chat at The Stephens Annual Investment Conference on Wednesday, November 15th, at 1:00 p.m. EST, at the Grand Hyatt in Nashville, TN.
  • A live webcast of the fireside chat will be available here .

Cerus Corporation Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.
  • Product gross margin for the third quarter of 2023 was 54.9% compared to 55.4% for the third quarter of 2022.
  • R&D expenses for the third quarter of 2023 were $16.8 million, compared to $16.2 million for the third quarter of 2022.
  • Net loss attributable to Cerus Corporation for the third quarter of 2023 was $7.3 million, or $0.04 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $8.5 million, or $0.05 per basic and diluted share, for the third quarter of 2022.

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

Retrieved on: 
Wednesday, November 1, 2023

Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace.

Key Points: 
  • Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace.
  • Bloodbuy’s flagship cloud-based platform connects hospitals, blood centers, and life sciences organizations using its multi-patented B2B e-commerce and computer networking technologies for blood and biological products.
  • View the full release here: https://www.businesswire.com/news/home/20231101749546/en/
    Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace (Photo: Business Wire)
    IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life.
  • Bloodbuy enables blood centers and hospitals, via its unique online marketplace, to redistribute available blood products quickly and easily across its vast network, taking the friction out of this mission critical activity.

Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023

Retrieved on: 
Thursday, October 19, 2023

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market.
  • ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
  • To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com.
  • A replay will be available on Cerus’ website and will be available approximately three hours after the call through November 16, 2023.

Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting

Retrieved on: 
Tuesday, October 10, 2023

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.
  • This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.
  • The following is a select list of presentations and abstracts of interest for Cerus.
  • Sunday, October 15, 2023 – 10:00 a.m.– Pathogen Reduced Cryoprecipitate: Early Experiences and Inventory Management Outcomes (Chair: M.S.

Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

Retrieved on: 
Wednesday, September 27, 2023

Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO).

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO).
  • Ms. Goodman will also serve as a member of the Company’s Executive Leadership Team.
  • “We are excited to welcome Alicia to the Cerus team,” said William “Obi” Greenman, Cerus’ president and chief executive officer.
  • “I am excited to be joining the Cerus team at this point in the Company’s remarkable journey to improve blood safety and availability,” said Ms. Goodman.

Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference

Retrieved on: 
Tuesday, September 12, 2023

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST.
  • A live webcast of the fireside chat will be available at https://wsw.com/webcast/cantor19/cers/2090781 .
  • A replay will be available for 90 days after the event.